AI data becomes sticking point in biopharma dealmaking

Big Pharma and AI biotech partnerships are stalling over who owns and controls AI-generated drug discovery data. Data rights, training set ownership and portability have become deal-breakers in biopharma M&A and licensing negotiations.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.